These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21817075)

  • 1. Clinicians adjust to latest ESA recommendations.
    Traynor K
    Am J Health Syst Pharm; 2011 Aug; 68(16):1467, 1472, 1474. PubMed ID: 21817075
    [No Abstract]   [Full Text] [Related]  

  • 2. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
    Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P
    Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
    Pashos CL; Larholt K; Fraser KA; McKenzie RS; Senbetta M; Piech CT
    Support Care Cancer; 2012 Jan; 20(1):159-65. PubMed ID: 21359879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No TREATment with darbepoetin dosed to hemoglobin 13 grams per deciliter in type 2 diabetes with pre-dialysis chronic kidney disease--safety warnings for erythropoiesis-stimulating agents.
    Curtiss FR; Fairman KA
    J Manag Care Pharm; 2009; 15(9):759-65. PubMed ID: 19954267
    [No Abstract]   [Full Text] [Related]  

  • 5. Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis.
    Barnett AL; Crémieux PY
    Pharmacotherapy; 2003 May; 23(5):690-3; discussion 693-4. PubMed ID: 12741447
    [No Abstract]   [Full Text] [Related]  

  • 6. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease.
    Agarwal AK
    Expert Opin Drug Saf; 2009 Mar; 8(2):145-53. PubMed ID: 19309243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
    Grabe DW
    Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Wilhelm-Leen ER; Winkelmayer WC
    Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment: the impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Lefebvre P; Vekeman F; Cremieux PY
    Ann Pharmacother; 2010 Mar; 44(3):595; author reply 595-6. PubMed ID: 20179253
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.
    Crouch Z; DeSantis ER
    Am J Health Syst Pharm; 2009 Jul; 66(13):1180-5. PubMed ID: 19535656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darbepoetin Alfa Versus Erythropoietin Alfa for Treatment of Renal Anemia in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage: A Randomized Non-inferiority Trial.
    Mehta KS; Sinha SD; Vamsi B; Reddy B; Naidu NR; Thakur PA; Sreenivasa C; Reddy VPR; Pandey R; Durugkar S
    J Assoc Physicians India; 2019 Jan; 67(1):62-66. PubMed ID: 30935177
    [No Abstract]   [Full Text] [Related]  

  • 15. Once-monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial.
    Campistol JM; Carreño A; Morales JM; Pallardó L; Franco A; Navarro D; Grinyó JM; Montenegro J; Sánchez Fructuoso AI; Romero R; Guirado L; Arias M;
    Transplantation; 2013 Jan; 95(2):e6-e10. PubMed ID: 23325012
    [No Abstract]   [Full Text] [Related]  

  • 16. Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.
    Einarson T; Machado M; Walker J; Iskedjian M
    Curr Med Res Opin; 2007 Jul; 23(7):1571-3; author reply 1573-4. PubMed ID: 17637205
    [No Abstract]   [Full Text] [Related]  

  • 17. New oversight put in place for physicians giving anemia drugs to patients with cancer.
    Mitka M
    JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885
    [No Abstract]   [Full Text] [Related]  

  • 18. Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis.
    Brown JN; Kemp DW; Brice KR
    Pharmacotherapy; 2009 Apr; 29(4):468-72. PubMed ID: 19323622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epoetin dosing and dialysis facility ownership.
    Regidor DL; Kalantar-Zadeh K; Kovesdy CP
    JAMA; 2007 Aug; 298(8):862; author reply 862-3. PubMed ID: 17712068
    [No Abstract]   [Full Text] [Related]  

  • 20. Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification.
    Liao SC; Hung CC; Lee CT; Lee CH; Lee CC; Lin CL; Sun CY; Cheng BC; Yang CC; Wu CH; Chen JB
    Ther Apher Dial; 2016 Aug; 20(4):400-7. PubMed ID: 27060362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.